|
STAAR Low-Grade Serous Ovarian Cancer Foundation is bringing LGSOC patients together for the first time for a conference to build community and focus on the specific challenges and latest research developments for this rare cancer. The two day conference will be held February 7-8, 2025, in Houston, Texas, and will include a visit to the research laboratories at the University of Texas, MD Anderson Cancer Center. What is STAAR? STAAR was founded in 2020 when three women facing low-grade serous ovarian cancer recognized the urgent need for dedicated funding and support—a need unmet by the larger charities. The foundation exists to fund research for better treatment options for low-grade serous carcinoma, a rare (about 5% of ovarian cancer cases) and extremely underfunded ovarian cancer. Conference Mission and Vision Mission: To empower patients, survivors, and caregivers by providing a supportive space to share experiences, access the latest medical information, and connect with resources that enhance their quality of life. Vision: To create a dynamic, informative, and inclusive gathering where attendees leave with a deeper understanding of low-grade ovarian cancer, empowered to make informed decisions about their care, and inspired by a community dedicated to advocacy, research, and support. Sessions include:
Keynote speakers Dr. David Gershenson is an unparalleled authority in the field of low-grade serous ovarian cancer with more than 47 years of dedicated experience at The University of Texas MD Anderson Cancer Center. His profound insights into LGSOC are the result of extensive clinical and translational research, making him the foremost authority in this field. With more than 450 peer-reviewed articles, 188 invited articles, book chapters, and editorials, Dr. Gershenson’s impact on LGSOC research is immeasurable. He served as Editor-In-Chief of the esteemed journal Gynecologic Oncology for 18 years and continues to contribute as Editor Emeritus. Dr. Rachel Grisham is an Associate Attending within the Department of Medicine at Memorial Sloan Kettering Cancer Center and Associate Professor of Medicine at Weill Cornell Medical College. She is board certified in Medical Oncology and is the Section Head of Ovarian Cancer Treatment and the Director of Gynecologic Medical Oncology at MSKCC Westchester. Dr. Grisham’s research focuses on determining the molecular drivers of low-grade serous ovarian cancer and the development of targeted treatment strategies for patients with recurrent ovarian cancer. She has served as the principal investigator for more than 25 clinical trials and serves on multiple committees within the American Society of Clinical Oncology, NRG Oncology, and Society of Gynecologic Oncology. She is the recipient of an ASCO Merit Award and a Conquer Cancer Career Development Award, as well as numerous other grants and awards. Social Media Assets (right click to save to your desktop)
0 Comments
Leave a Reply. |
Archives
December 2024
Categories |
RSS Feed
